Agreements

Date: 2015-01-08

Type of information: Commercialisation agreement

Compound: delafloxacin

Company: Melinta Therapeutics (USA - CT) Eurofarma Laboratórios (Brazil)

Therapeutic area: Infectious diseases

Type agreement: commercialisation - distribution

Action mechanism:

antibiotic. Delafloxacin is an investigational anionic fluoroquinolone antibiotic currently in Phase 3 clinical development for hospital-treated skin infections, known as acute bacterial skin and skin structure infections (ABSSSI). In clinical trials, delafloxacin is being tested in both IV and oral formulations.

Disease: acute bacterial skin and skin structure infections (ABSSSI)

Details:

• On January 8, 2015, Melinta Therapeutics and Eurofarma Laboratórios announced that the companies have entered into commercialization and distribution agreements for delafloxacin. Under the terms of the agreements, Eurofarma will be responsible for obtaining regulatory approval in Brazil and will then have the right to market, sell and distribute delafloxacin in that country for the treatment of acute bacterial skin and skin structure infections (ABSSSI).
Delafloxacin is currently in Phase 3 clinical development comparing the efficacy and safety of oral and intravenous delafloxacin to a control regimen of I.V. vancomycin plus aztreonam in adults with ABSSSI.

Financial terms:

Melinta will receive a combined upfront cash and equity payment of $15 million, as well as milestones and royalties on future sales of delafloxacin.

Latest news: